JOHNSON & JOHNSON is 197.5x more valuable than Arcutis Biotherapeutics, Inc. by market capitalization ($573.98 B vs $2.91 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | ARQT | JNJ |
|---|---|---|
| Market cap | $2.91 B | $573.98 B |
| US-listed rank | #1831 | #20 |
| Revenue (latest FY) | $376.07M | $94.19B |
| Net income (latest FY) | -$16.14M | $26.80B |
| Net margin | -4.3% | 28.5% |
| P/E (trailing FY) | - | 21.4 |
| SEC filings | 798 | 984 |
JOHNSON & JOHNSON is 197.5x more valuable than Arcutis Biotherapeutics, Inc. by market capitalization ($573.98 B vs $2.91 B).
In their latest fiscal years, Arcutis Biotherapeutics, Inc. reported $376.07M in revenue while JOHNSON & JOHNSON reported $94.19B.
Full pages: Arcutis Biotherapeutics, Inc. and JOHNSON & JOHNSON, or browse the full rankings.